Europe • Euronext Paris • EPA:IPN • FR0010259150
Taking everything into account, IPN scores 6 out of 10 in our fundamental rating. IPN was compared to 55 industry peers in the Pharmaceuticals industry. IPN has an excellent financial health rating, but there are some minor concerns on its profitability. IPN is not valued too expensively and it also shows a decent growth rate.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.56% | ||
| ROE | 10.59% | ||
| ROIC | 14.89% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 26.02% | ||
| PM (TTM) | 11.92% | ||
| GM | 83.32% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.2 | ||
| Debt/FCF | 1.46 | ||
| Altman-Z | 4.77 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.98 | ||
| Quick Ratio | 1.8 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 13.4 | ||
| Fwd PE | 12.06 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 19.39 | ||
| EV/EBITDA | 6.49 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.03% |
ChartMill assigns a fundamental rating of 6 / 10 to IPN.PA.
ChartMill assigns a valuation rating of 6 / 10 to IPSEN (IPN.PA). This can be considered as Fairly Valued.
IPSEN (IPN.PA) has a profitability rating of 6 / 10.
The financial health rating of IPSEN (IPN.PA) is 7 / 10.
The dividend rating of IPSEN (IPN.PA) is 4 / 10 and the dividend payout ratio is 25.94%.